Royal Philips announced the introduction of HeartModelA.I., a new Anatomically Intelligent Ultrasound (AIUS) tool that brings advanced quantification, automated 3-D views and robust reproducibility to cardiac ultrasound imaging. Philips' fastest 3-D AIUS ultrasound measurement method was unveiled on its Epiq 7 ultrasound system during the American Society of Echocardiography (ASE) annual meeting in Boston.

Researchers announced the results of a study to develop and validate a model, comprised of echocardiographic and clinical data, to predict three-year mortality of patients hospitalized in coronary care units (CCU). The results describe an integrated score for three-year mortality of CCU patients, comprised of fewer variables and better/equal predictive value compared to existing scores.

A research team from New York has announced advances in automated echocardiography decision systems that could help clinicians more accurately assess complex heart disease. The team developed a system that takes a large amount of information from ultrasound images, learns about the structure and function of the heart, and automatically differentiates enlarged hearts seen in patients with hypertrophic cardiomyopathy (HCM) from a normal variation of enlarged hearts seen in athletes. The two conditions are often difficult to distinguish from each other, and misdiagnoses might have major implications, since undiagnosed HCM is one of the most common causes of sudden cardiac death in athletes, while thickening seen in athlete's heart is benign and does not generally lead to dysfunction.

Researchers announced results of a new study which demonstrated that smartphone-based mHealth devices, coupled with handheld echocardiography, can provide improved assessment and are readily integrated at the point-of-care for evaluation of patients with structural heart diseases. This study was conducted as part of the American Society of Echocardiography (ASE) Foundation’s Valvular Assessment Leading to Unexplored Echocardiographic Stratagems (VALUES) program, a four-day teaching and research event held at the Sri Sathya Sai Institute of Higher Medical Sciences in Bangalore, India, August 11-14, 2014. Over the course of several days, researchers assessed patients with multiple forms of rheumatic valvular heart disease with either standard diagnostic equipment or mobile health-based devices.

June 12, 2015 — Fujifilm Medical Systems U.S.A. Inc. will demonstrate the latest generation of Synapse Cardiovascular version 6.0 at the American Society of Echocardiography (ASE) 26th Annual Scientific Sessions, June 13 – 15 in Boston. Synapse Cardiovascular version 6.0 is a total re-engineering of Fujifilm’s solution for echo reporting.

A first-in-human study shows how a powerful new drug finds and attaches itself to the ovarian and prostate cancer cells for both imaging and personalized cancer treatment. Study results were revealed at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Neuroinflammation caused by a reactive immune system could be tripping off the neurodegeneration seen in certain dementias, multiple sclerosis and other deadly diseases of the nervous system. A novel molecular imaging technique could be the key to understanding how best to treat these and other devastating diseases, according to a recent study presented at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Siemens’ PETNET Solutions Inc. has entered into a nationwide agreement with U.K.-based Blue Earth Diagnostics Ltd. for the exclusive commercial manufacturing and distribution of Fluciclovine (18F), an investigational positron emission tomography and computed tomography (PET/CT) radiopharmaceutical. Fluciclovine (18F) is being studied for prostate imaging in clinical trials conducted in the United States, Japan, Italy, Norway, Sweden and Finland. The F-18-based radiopharmaceutical has a long half-life, which may facilitate its geographical distribution to clinical trial sites and then to clinical imaging centers once it gains approval from the U.S. Food and Drug Administration (FDA).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now